Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01377948 · ClinicalTrials.gov registry record · Phase 1
Reducing Aggression in Children and Adolescent on an Inpatient Unit
A Phase 1 study of Aggression and Anger, sponsored by Gonzalez-Heydrich, Joseph, M.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01377948 is a Phase 1 study of Aggression and Anger that has completed, run by Gonzalez-Heydrich, Joseph, M.D.. The registered enrollment target is 20 participants, below the 154-participant average among 21 other Aggression trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01377948, a Phase 1 study of Aggression and Anger, has completed, sponsored by Gonzalez-Heydrich, Joseph, M.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether Anger Control Therapy (ACT) with Regulate and Gain Emotional-Control (RAGE-Control) is a feasible behavioral therapy to provide on a pediatric inpatient psychiatric unit.
Conditions Studied
Interventions
- BEHAVIORAL ACT with RAGE-Control
Study Locations (1)
Massachusetts
- Children's Hospital Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01377948
The ClinicalTrials.gov registry entry for NCT01377948 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 154-participant average among 21 other Aggression trials with a reported enrollment target (87% lower). The listed sponsor is Gonzalez-Heydrich, Joseph, M.D., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Aggression appearing as the primary indexed condition, and to 1 intervention - of which ACT with RAGE-Control is the first listed.
NCT01377948 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01377948 about?
NCT01377948 is a clinical study titled "Reducing Aggression in Children and Adolescent on an Inpatient Unit". The purpose of this study is to determine whether Anger Control Therapy (ACT) with Regulate and Gain Emotional-Control (RAGE-Control) is a feasible behavioral therapy to provide on a pediatric inpatient psychiatric unit.
What is the current status of trial NCT01377948?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-06. Estimated completion is 2011-10.
What conditions does trial NCT01377948 study?
This clinical trial studies the following conditions: Aggression, Anger.
What interventions are being tested in trial NCT01377948?
The interventions under investigation include: ACT with RAGE-Control (BEHAVIORAL).
Who is sponsoring clinical trial NCT01377948?
This trial is sponsored by Gonzalez-Heydrich, Joseph, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01377948 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aggression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Manage Emotions to Reduce Aggression (MERA)
RECRUITING · NA
-
Manualized Assessment and Treatment Model of Challenging Behavior
RECRUITING · NA
-
Refinements of Functional Communication Training
RECRUITING · NA
-
Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism
RECRUITING · Phase 2
-
Clinical Trial on Agitation in Alzheimer's Dementia
RECRUITING · Phase 2
-
Addressing Root Causes for Gun Violence Prevention (ARC-GVP)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.